AN2 Therapeutics, Inc. (ANTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
1800 El Camino Real
Menlo Park, CA 94027
United States of America (the)
Phone
650-331-9090
Sector
Healthcare
Industry
Biotechnology
Employees
22
First IPO Date
March 25, 2022
| Name | Title | Pay | Year Born |
| Eric E. Easom | Co-Founder, Chief Executive Officer, President & Chairman of the Board | 943,313 | 1968 |
| Joseph S. Zakrzewski | Co-Founder & Independent Director | 51,500 | 1962 |
| Josh Eizen | Chief Legal Officer, Chief Operating Officer & Corporate Secretary | 630,000 | 1979 |
| Lucy O. Day | CFO, & Principal Financial Officer | 633,580 | 1960 |
| Sanjay Chanda | Chief Development Officer | 0 | 1966 |
| Sarah Williams | Vice President of Controller & Principal Accounting Officer | 0 | 1988 |
| Michael R. K. Alley | Co-Founder, Senior Vice President of Research Fellow & Head of Biology | 0 | N/A |
| Vince Hernandez | Senior Vice President of Research & Head of Chemistry | 0 | N/A |
| George Harrison Talbot FACP | Co-Founder & Senior Clinical Advisor | 0 | 1948 |
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.